Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. 2001

M Wiench, and Z Wygoda, and E Gubala, and J Wloch, and K Lisowska, and J Krassowski, and D Scieglinska, and A Fiszer-Kierzkowska, and D Lange, and D Kula, and M Zeman, and J Roskosz, and A Kukulska, and Z Krawczyk, and B Jarzab
Departments of Nuclear Medicine and Endocrine Oncology, Center of Oncology, Maria Sklodowska-Curie Memorial Institute, Gliwice, Poland.

OBJECTIVE The study was undertaken to evaluate the frequency of inherited medullary thyroid carcinoma (MTC) among patients with apparent sporadic disease. A stepwise algorithm was used depending on clinical indices and the age of patient at MTC diagnosis. METHODS One hundred sixteen patients with MTC verified by postoperative pathologic examination were subjected to genetic analysis of RET exons 10, 11, 13, 14, and 16 by means of polymerase chain reaction, restriction endonuclease digestion, and DNA sequencing. RESULTS Among 116 apparent sporadic MTC patients, we identified eleven (9.5%) RET germline mutation carriers. Seven of these (6.0%) were found by routine analysis (exons 10 and 11). The frequency of inherited disease among patients younger than 45 years at diagnosis was 10.2% by analysis of typical mutations in exons 10 and 11. Extended genetic analysis (sequencing of exons 11, 13, 14, and 16) yielded 6.1% additional diagnoses, giving a risk of 16.3% in this age group. One previously unreported mutation in exon 11 affected codon 649 (TCG>TTG, Ser>Leu). In the true sporadic MTC patients younger than 30 years at diagnosis, frequencies of 36% and 4.5% in polymorphic variants L769L and S836S, respectively, were observed. The frequency for L769L was higher than in older patients (P <.05). CONCLUSIONS The frequency of inherited disease among apparent sporadic medullary thyroid carcinoma patients is close to 10% in the Polish population of MTC patients. The extended analysis of all known RET proto-oncogene mutation sites is obligatory in patients younger than 45 years at diagnosis, but we also see the need to analyze the impact of rarer mutations in older patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010375 Pedigree The record of descent or ancestry, particularly of a particular condition or trait, indicating individual family members, their relationships, and their status with respect to the trait or condition. Family Tree,Genealogical Tree,Genealogic Tree,Genetic Identity,Identity, Genetic,Family Trees,Genealogic Trees,Genealogical Trees,Genetic Identities,Identities, Genetic,Tree, Family,Tree, Genealogic,Tree, Genealogical,Trees, Family,Trees, Genealogic,Trees, Genealogical
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000090063 Proto-Oncogene Mas A protein that is encoded by the MAS1 gene. It is a receptor for ANGIOTENSIN 1-7 and acts as an antagonist of ANGIOTENSIN-2 TYPE 1 RECEPTOR. C-Mas Protein,II-Proto-Oncogene Proteins, Cellular,Mas Protein,Mas1 Protein,Proto-Oncogene Protein Mas,Proto-Oncogene Proteins C-Mas-1,C Mas Protein,C-Mas-1, Proto-Oncogene Proteins,Cellular II-Proto-Oncogene Proteins,II Proto Oncogene Proteins, Cellular,Mas, Proto-Oncogene,Protein Mas, Proto-Oncogene,Protein, C-Mas,Protein, Mas,Protein, Mas1,Proteins, Cellular II-Proto-Oncogene,Proto Oncogene Mas,Proto Oncogene Proteins C Mas 1
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013964 Thyroid Neoplasms Tumors or cancer of the THYROID GLAND. Cancer of Thyroid,Thyroid Cancer,Cancer of the Thyroid,Neoplasms, Thyroid,Thyroid Adenoma,Thyroid Carcinoma,Adenoma, Thyroid,Adenomas, Thyroid,Cancer, Thyroid,Cancers, Thyroid,Carcinoma, Thyroid,Carcinomas, Thyroid,Neoplasm, Thyroid,Thyroid Adenomas,Thyroid Cancers,Thyroid Carcinomas,Thyroid Neoplasm
D017668 Age of Onset The age, developmental stage, or period of life at which a disease or the initial symptoms or manifestations of a disease appear in an individual. Age-at-Onset,Age at Onset,Onset Age

Related Publications

M Wiench, and Z Wygoda, and E Gubala, and J Wloch, and K Lisowska, and J Krassowski, and D Scieglinska, and A Fiszer-Kierzkowska, and D Lange, and D Kula, and M Zeman, and J Roskosz, and A Kukulska, and Z Krawczyk, and B Jarzab
May 2013, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP),
M Wiench, and Z Wygoda, and E Gubala, and J Wloch, and K Lisowska, and J Krassowski, and D Scieglinska, and A Fiszer-Kierzkowska, and D Lange, and D Kula, and M Zeman, and J Roskosz, and A Kukulska, and Z Krawczyk, and B Jarzab
February 1988, Lancet (London, England),
M Wiench, and Z Wygoda, and E Gubala, and J Wloch, and K Lisowska, and J Krassowski, and D Scieglinska, and A Fiszer-Kierzkowska, and D Lange, and D Kula, and M Zeman, and J Roskosz, and A Kukulska, and Z Krawczyk, and B Jarzab
January 2006, Thyroid : official journal of the American Thyroid Association,
M Wiench, and Z Wygoda, and E Gubala, and J Wloch, and K Lisowska, and J Krassowski, and D Scieglinska, and A Fiszer-Kierzkowska, and D Lange, and D Kula, and M Zeman, and J Roskosz, and A Kukulska, and Z Krawczyk, and B Jarzab
January 2022, Acta endocrinologica (Bucharest, Romania : 2005),
M Wiench, and Z Wygoda, and E Gubala, and J Wloch, and K Lisowska, and J Krassowski, and D Scieglinska, and A Fiszer-Kierzkowska, and D Lange, and D Kula, and M Zeman, and J Roskosz, and A Kukulska, and Z Krawczyk, and B Jarzab
January 2020, Technology in cancer research & treatment,
M Wiench, and Z Wygoda, and E Gubala, and J Wloch, and K Lisowska, and J Krassowski, and D Scieglinska, and A Fiszer-Kierzkowska, and D Lange, and D Kula, and M Zeman, and J Roskosz, and A Kukulska, and Z Krawczyk, and B Jarzab
March 1993, Endocrine pathology,
M Wiench, and Z Wygoda, and E Gubala, and J Wloch, and K Lisowska, and J Krassowski, and D Scieglinska, and A Fiszer-Kierzkowska, and D Lange, and D Kula, and M Zeman, and J Roskosz, and A Kukulska, and Z Krawczyk, and B Jarzab
October 1994, Human molecular genetics,
M Wiench, and Z Wygoda, and E Gubala, and J Wloch, and K Lisowska, and J Krassowski, and D Scieglinska, and A Fiszer-Kierzkowska, and D Lange, and D Kula, and M Zeman, and J Roskosz, and A Kukulska, and Z Krawczyk, and B Jarzab
December 2005, Thyroid : official journal of the American Thyroid Association,
M Wiench, and Z Wygoda, and E Gubala, and J Wloch, and K Lisowska, and J Krassowski, and D Scieglinska, and A Fiszer-Kierzkowska, and D Lange, and D Kula, and M Zeman, and J Roskosz, and A Kukulska, and Z Krawczyk, and B Jarzab
October 1994, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
M Wiench, and Z Wygoda, and E Gubala, and J Wloch, and K Lisowska, and J Krassowski, and D Scieglinska, and A Fiszer-Kierzkowska, and D Lange, and D Kula, and M Zeman, and J Roskosz, and A Kukulska, and Z Krawczyk, and B Jarzab
January 2006, World journal of surgery,
Copied contents to your clipboard!